The Directory of Open Access Journals
DOAJ Logotype
Open
Global
Trusted
Main actions
Support
Institutions and libraries
Publishers
Institutional and library supporters
Apply
Application form
Guide to applying
The DOAJ Seal
Transparency & best practice
Publisher information
Licensing & copyright
Search
Menu
Secondary actions
Search
Journals
Articles
Documentation
API
OAI-PMH
Widgets
Public data dump
OpenURL
XML
Metadata help
Preservation
About
About DOAJ
DOAJ at 20
DOAJ team
Ambassadors
Advisory Board & Council
Editorial Policy Advisory Group
Volunteers
News
Support
Institutions and libraries
Publishers
Institutional and library supporters
Apply
Application form
Guide to applying
The DOAJ Seal
Transparency & best practice
Publisher information
Licensing & copyright
Login
Login
Quick search
Close
×
Journals
Articles
Search by keywords:
In the field:
In all fields
Title
ISSN
Subject
Publisher
Country of publisher
Search
Oncology and Therapy
(Nov 2023)
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
Heidi Ko,
Rebecca A. Previs,
Kyle C. Strickland,
Jonathan Klein,
Brian Caveney,
Chiara Chiruzzi,
Marcia Eisenberg,
Eric A. Severson,
Shakti Ramkissoon,
Kamal S. Saini
Affiliations
Heidi Ko
Labcorp Oncology
Rebecca A. Previs
Labcorp Oncology
Kyle C. Strickland
Labcorp Oncology
Jonathan Klein
Labcorp Oncology
Brian Caveney
Labcorp Oncology
Chiara Chiruzzi
Fortrea Inc
Marcia Eisenberg
Labcorp Oncology
Eric A. Severson
Labcorp Oncology
Shakti Ramkissoon
Labcorp Oncology
Kamal S. Saini
Fortrea Inc
DOI
https://doi.org/10.1007/s40487-023-00249-0
Journal volume & issue
Vol. 12, no. 1
pp. 13 – 17
Abstract
Read online
No abstracts available.
Keywords
HER2-low
Metastatic breast cancer
HER2 testing
HER2-directed antibody–drug conjugate
WeChat QR code
Close